SARS Research Lab Loses 2,000 Tubes of Killer Virus – foul play has not been ruled out

See on Scoop.itBiodefense News


A prestigious research institute in France said it had lost thousands of tubes of samples of the deadly Sars coronavirus.

A routine inventory check at Paris’ Pasteur Institute revealed that 2,349 tubes containing fragments of the virus responsible for the deaths of 774 people in 2002 were missing, the centre named after French chemist Louis Pasteur said.

The institute was quick to reassure the public and said that the contents of the missing vials had no infectious potential. They contained only part of the virus and had no ability to spread.

“Independent experts referred by health authorities have qualified such potential as ‘non-existing’ according to the available evidence and literature on the survival of the Sars virus,” the institute said.

In 2002 more than 8,000 people were infected by a pandemic of Sars – severe acute respiratorysyndrome. The virus spread from China through Hong Kong and on to other countries before it was eventually brought under control.

It is not clear how the tubes disappeared from one of the institute’s safest laboratories. Management were made aware of the loss in January, Le Monde newspaper reported.

For weeks, staff at the institute tried to find the missing vials, general director Christian Bréchot said.

“We’ve looked for those boxes [containing the tubes] everywhere,” Bréchot explained.

“We went thought the lists of all the people who have worked here in the past year and a half, including trainees. We have scrutinised their profile to check if there was any conflict.”

Bréchot said that foul play was “highly improbable” but had not been ruled out.


See on www.ibtimes.co.uk

PharmAthene Presents New SparVax® Anthrax Vaccine Data At The American Society For Microbiology 2014 Meeting

See on Scoop.itBiodefense News

ANNAPOLIS, Md., May 29, 2014 /PRNewswire/ — PharmAthene, Inc. (NYSE MKT: PIP) announced today that new analytical data from the Company’s SparVax® anthrax vaccine program were presented at the 114th General Meeting of the American Society for Microbiology (ASM), held recently in Boston, Massachusetts. In a poster presentation entitled “Evidence Correlating Changes in Structure and Biological Activity for a Recombinant Protective Antigen (rPA) Anthrax Vaccine,” Dr. Bradford Powell, Director, Analytical Sciences at PharmAthene, presented the Company’s achievements in developing new analytical methods to measure how changes in the structural characteristics of rPA impact the potency and stability of the vaccine product, an important requirement for licensure by the United States Food and Drug Administration (FDA).  Specifically, deamidation of rPA has been identified as the major pathway of degradation, and methods were developed to assess the state of deamidation over time and its relationship to vaccine potency.  The results of the study confirmed a strong positive correlation between the structural and functional stability of rPA.


See on ca.finance.yahoo.com